Rohit Aggarwal, MD, MS

University of Pittsburgh
Pittsburgh, PA, United States

Dr. Aggarwal is a professor of medicine at University of Pittsburgh and medical director of Arthritis and Autoimmunity Center at University of Pittsburgh Medical Center. He is the co-Director of UPMC Myositis Center. His research and clinical areas of interest are clinical and translational research in inflammatory muscle diseases (myositis) and associated interstitial lung disease. He is the past-chair of the medical advisory board of The Myositis Association (TMA) as well as past-chair of the scientific committee of IMACS, which are the largest patient and physician groups working in the field of myositis, respectively.

Disclosure information not submitted.

Presentation(s):

• 521: CH Myositis: Myopathy: Issues in Diagnosis and Treatment Viewpoint

  Saturday, November 12, 2022
  1:00 PM – 1:30 PM Eastern Time

• 0157: Brepocitinib for the Treatment of Dermatomyositis: Pharmacologic and Clinical Rationale

  Saturday, November 12, 2022
  1:00 PM – 3:00 PM Eastern Time

• 539: CH Myositis: Challenging Case

  Saturday, November 12, 2022
  1:35 PM – 2:05 PM Eastern Time

• 551: CH Myositis: Virtual Background Happy Hour and Meet the Master

  Saturday, November 12, 2022
  6:00 PM – 6:45 PM Eastern Time

• 568: CH Myositis: The ABCs in Myositis: Autoantibodies and Beyond

  Sunday, November 13, 2022
  1:00 PM – 1:45 PM Eastern Time

• 586: CH Myositis: Challenging Case ILD

  Sunday, November 13, 2022
  2:00 PM – 2:45 PM Eastern Time

• 607: CH Myositis: Key Abstracts

  Monday, November 14, 2022
  1:00 PM – 2:00 PM Eastern Time

• 617: CH Myositis: Poster Presenter Lightening Round

  Monday, November 14, 2022
  2:05 PM – 2:50 PM Eastern Time

• 2237: Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Subcutaneous Abatacept in Adults with Active Idiopathic Inflammatory Myopathy: Results of the 24-Week Double-Blind and 28-Week Open-Label Periods

  Monday, November 14, 2022
  4:30 PM – 4:40 PM Eastern Time

• 2239: Effect of Treatment with IVIG (octagam10%) on Skin Symptoms and Quality of Life in Subjects with Dermatomyositis. Results of a Large, Randomized, Placebo-controlled International Phase III Trial

  Monday, November 14, 2022
  5:00 PM – 5:10 PM Eastern Time